Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 251 - 275 of 386

  1. Hanly SM, Rimsky LT, Malim MH, Kim JH, Hauber J, Duc Dodon M, Le SY, Maizel JV, Cullen BR, Greene WC. Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev. 1989 Oct; 3(10):1534-44.
  2. Cullen BR, Greene WC. Regulatory pathways governing HIV-1 replication. Cell. 1989 Aug 11; 58(3):423-6.
  3. Greene WC, Böhnlein E, Ballard DW. HIV-1, HTLV-1 and normal T-cell growth: transcriptional strategies and surprises. Immunol Today. 1989 Aug; 10(8):272-8.
  4. Böhnlein E, Ballard DW, Bogerd H, Peffer NJ, Lowenthal JW, Greene WC. Induction of interleukin-2 receptor-alpha gene expression is regulated by post-translational activation of kappa B specific DNA binding proteins. J Biol Chem. 1989 May 25; 264(15):8475-8.
  5. Lowenthal JW, Ballard DW, Bogerd H, Böhnlein E, Greene WC. Tumor necrosis factor-alpha activation of the IL-2 receptor-alpha gene involves the induction of kappa B-specific DNA binding proteins. J Immunol. 1989 May 01; 142(9):3121-8.
  6. Hoyos B, Ballard DW, Böhnlein E, Siekevitz M, Greene WC. Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science. 1989 Apr 28; 244(4903):457-60.
  7. Böhnlein E, Siekevitz M, Ballard DW, Lowenthal JW, Rimsky L, Bogérd H, Hoffman J, Wano Y, Franza BR, Greene WC. Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins. J Virol. 1989 Apr; 63(4):1578-86.
  8. Lowenthal JW, Ballard DW, Böhnlein E, Greene WC. Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2331-5.
  9. Böhnlein E, Lowenthal JW, Wano Y, Franza BR, Ballard DW, Greene WC. HIV-1, HTLV-I and the interleukin-2 receptor: insights into transcriptional control. Haematol Blood Transfus. 1989; 32:393-401.
  10. Wano Y, Feinberg M, Hosking JB, Bogerd H, Greene WC. Stable expression of the tax gene of type I human T-cell leukemia virus in human T cells activates specific cellular genes involved in growth. Proc Natl Acad Sci U S A. 1988 Dec; 85(24):9733-7.
  11. Fung MR, Ju G, Greene WC. Co-internalization of the p55 and p70 subunits of the high-affinity human interleukin 2 receptor. Evidence for a stable ternary receptor complex. J Exp Med. 1988 Nov 01; 168(5):1923-8.
  12. Rimsky L, Hauber J, Dukovich M, Malim MH, Langlois A, Cullen BR, Greene WC. Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature. 1988 Oct 20; 335(6192):738-40.
  13. Collins L, Tsien WH, Seals C, Hakimi J, Weber D, Bailon P, Hoskings J, Greene WC, Toome V, Ju G. Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1988 Oct; 85(20):7709-13.
  14. Ballard DW, Böhnlein E, Lowenthal JW, Wano Y, Franza BR, Greene WC. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988 Sep 23; 241(4873):1652-5.
  15. Froussard P, Chastagner P, Sommé G, Abadie A, Greene W, Thèze J, Longacre S. p55 IL-2 receptor mRNA precursors in murine T lymphocyte nuclei. J Immunol. 1988 Aug 15; 141(4):1358-64.
  16. Böhnlein E, Lowenthal JW, Siekevitz M, Ballard DW, Franza BR, Greene WC. The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell. 1988 Jun 03; 53(5):827-36.
  17. Lowenthal JW, Böhnlein E, Ballard DW, Greene WC. Regulation of interleukin 2 receptor alpha subunit (Tac or CD25 antigen) gene expression: binding of inducible nuclear proteins to discrete promoter sequences correlates with transcriptional activation. Proc Natl Acad Sci U S A. 1988 Jun; 85(12):4468-72.
  18. Cullen BR, Podlaski FJ, Peffer NJ, Hosking JB, Greene WC. Sequence requirements for ligand binding and cell surface expression of the Tac antigen, a human interleukin-2 receptor. J Biol Chem. 1988 Apr 05; 263(10):4900-6.
  19. Greene WC. Sarcoidosis and interleukin-2 receptors. Am Rev Respir Dis. 1988 Apr; 137(4):757-8.
  20. Zeitz M, Greene WC, Peffer NJ, James SP. Lymphocytes isolated from the intestinal lamina propria of normal nonhuman primates have increased expression of genes associated with T-cell activation. Gastroenterology. 1988 Mar; 94(3):647-55.
  21. Greene WC. In: Gallin J, Goldstein I, Snyderman R (Eds.), Inflammation: Basic principles and clinical correlations. IL-2, IL-2 receptors, and the growth of human T cells. 1988; 209-288.
  22. Wano Y, Dukovich M, Kehrl JH, Greene WC. In: Smith KA (Ed.), Interleukin 2. New perspectives on the structure of the human high affinity i nterleukin-2 receptor. 1988; 99-112.
  23. Greene WC. In: Gallin J, Goldstein I, Snyderman R (Eds.), Inflammation: Basic principles and clinical correlations. IL-2, IL-2 receptors, and the growth of human T cells. 1988; 209-288.
  24. Wano Y, Dukovich M, Kehrl JH, Greene WC. In: Smith KA (Ed.), Interleukin 2. New perspectives on the structure of the human high affinity i nterleukin-2 receptor. 1988; 99-112.
  25. Greene WC, Wano YJ, Dukovich M. New insights into the structure of high-affinity interleukin-2 receptors. Recent Prog Horm Res. 1988; 44:141-55.